High-risk melanoma: Accuracy of FDG PET/CT with added CT morphologic information for detection of metastases

Radiology

Volumn 244, Issue 2, 2007, Pages 566-574

  Strobel, Klaus ^a   Dummer, Reinhard ^b   Husarik, Daniela B ^a   Lago, Marisol Pérez ^a   Hany, Thomas F ^a   Steinert, Hans C ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE;

ADOLESCENT; ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; INSTITUTIONAL REVIEW; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MCNEMAR TEST; MELANOMA; METASTASIS; MUSCLE METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSOAS MUSCLE; SENSITIVITY AND SPECIFICITY; SKIN METASTASIS; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34447525261     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2442061099     Document Type: Article

References (35)

1. Eigtved A, Andersson AP, Dahlstrom K, et al. Use of fluorine-18 fluorodeoxyglucose positron emission tomographyin the detection of silent metastases from malignant melanoma. Eur J Nucl Med 2000;27:70-75.
2. Gritters LS, Francis IR, Zasadny KR, Wahl RL. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med 1993;34:1420-1427.
3. Schwimmer J, Essner R, Patel A, et al. A review of the literature for whole-body FDG PFT in the management of patients with melanoma. Q J Nucl Med 2000;44:153-167.
4. Steinert HC, Huch Boni KA, Buck A, et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D- glucose. Radiology 1995;195:705-709.
5. Gulec SA, Faries MB, Lee CC, et al. The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impael on surgical decision making. Clin Nucl Med 2003;28:961-965.
6. Swetter SM, Carroll LA, Johnson DL, Segall GM. Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. Ann Surg Oncol 2002;9:646-653.
7. Engel H, Steinert H, Buck A, Berthold T, Huch Boni RA, von Schulthess GK. Whole-body PFT: physiological and artifactual fluorodeoxyglucose accumulations. J Nucl Med 1996;37:441-446.
8. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Kur J Nucl Med 1996;23:1409-1415.
9. Cook GJ, Maisey MN, Fogelman I. Normal variants, artefacts and interpretative pitfalls in PFT imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med 1999;26:1363-1378.
10. Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med 1996;26:308-314.
11. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radio-Graphics 1999;19:61-77.
12. Hafner J, Schmid MH, Kempf W, et al. Baseline staging in cutaneous malignant melanoma. Br J Dermatol 2004;150:677-686.
13. Crippa F, Leutner M, Belli F, et al. Which kinds of lymph node metastases can FDG PET detect? a clinical study in melanoma. J Nucl Med 2000;41:1491-1494.
14. Acland KM, Healy C, Calonje F, et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol 2001;19:2674-2678.
15. Wagner JD, Schauwecker DS, Davidson D, Wenck S, Jung SH, Hutchins G. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol 2001;77:237-242.
16. Rinne D, Baum RP, Hor G, Kaufmann R. Primary staging and follow-up of high risk melanoma patients with whole-hody 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 1998;82:1664-1071.
17. Nguyen AT, Akhurst T, Larson SM, Coit DG, Brady MS. PET scanning with (18)F 2-fluoro-2-deoxy-D-glucose (FDG) in patients with melanoma: benefits and limitations. Clin Positron Imaging 1999;2:93-98.
18. Hany TF, Gharelipapagh K, Kamel EM, Buck A, Himms-Hagen J, von Schulthess GK. Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region. Eur J Nucl Med Mol Imaging 2002;29:1393-1398.
19. Kamel KM, Goerres GW, Burger C, von Schulthess GK, Steinert HC. Recurrent laryngeal nerve palsy in patients with lung cancer: detection with PET-CT image fusion - report of six cases. Radiology 2002; 224:153-156.
20. Delbeke D, Coleman RK, Guiborteau MJ, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 2006;47:885-895.
21. Jury CS, McAllister KJ, MacKie RM. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br J Dermatol 2000;143:269-274.
22. Aquino SL, Kuester LB, Muse VV, Halpern EF, Fischman AJ. Accuracy of transmission CT and FDG-PET in the detection of small pulmonary nodules with integrated PET/CT. Eur J Nucl Med Mol Imaging 2000;33:692-696.
23. Reinhardt MJ, Wiethoelter N, Matthies A, et al. PET recognition of pulmonary metastases on PET/CT imaging: impact of attenuation-corrected and non-attenuation-corrected PET images. Eur J Nucl Med Mol Imaging 2006;33:134-139.
24. Lowe VJ, DeLong DM, Hoffman JM, Coleman RE. Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy. J Nucl Med 1995;36:883-887.
25. Henschke CI, Yankelevitz DF, Naidich DP, et al. CT screening for lung cancer; suspiciousness of nodules according to size on baseline scans. Radiology 2004;231:164-168.
26. Aberle DR, Gamsu G, Heuschke CI, Naidich DP, Swensen SJ. A consensus statement of the Society of Thoracic Radiology: screening for lung cancer with helical computed tomography. J Thorac Imaging 2001;16:65-68.
27. Swensen SJ, Silverstein MD, Ilstrup DM, Schleck CD, Edell ES. The probability of malignancy in solitary pulmonary nodules: application to small radiologically indeterminate nodules. Arch Intern Med 1997;157: 849-855.
28. MacMahon H, Austin JH, Gamsu G, et al. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology 2005;237:395-400.
29. Hany TF, Steinert HC, Goerres GW, Buck A, von Schulthess GK. PET diagnostic accuracy: improvement with in-line PET-CT system - initial results. Radiology 2002;225: 575-381.
30. Gearhart SL, Frassica D, Rosen R, Choti M, Schulick R, Wahl R. Improved staging with pretreatment positron emission tomography/computed tomography in low rectal cancer. Ann Surg Oncol 2006;13:397-404.
31. Osman MM, Cohade C, Fishman EK, Wahl RL. Clinically significant incidental findings on the unenhanced CT portion of PET/CT studies: frequency in 250 patients. J Nucl Med 2005;46:1352-1355.
32. Schoder H, Yeung HW, Larson SM. CT in PET/CT: essential features of interpretation. J Nucl Med 2005;46:1249-1251.
33. Yeung HW, Schoder H, Smith A, Gonen M, Larson SM. Clinical value of combined positron emission tomography/computed tomography imaging in the interpretation of 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography studies in cancer patients. Mol Imaging Biol 2005;7:229-233.
34. Reinhardt MJ, Joe AY, Jaeger U, et al. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 2006;24:1178-1187.
35. Kamel IR, Cohade C, Neyman L, Fishman EK, Wahl RL. Incremental value of CT in PET/CT of patients with colorectal carcinoma. Ahdom Imaging 2004;29:663-668.